Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but lowered the price target from $32 to $30.

May 09, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Syndax Pharmaceuticals but lowers the price target from $32 to $30.
While the reduction in price target could suggest a slightly less optimistic view on the stock's future price performance, the maintenance of a Buy rating indicates a continued positive outlook on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the sustained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100